Emerson Electric Up Over 10%, On Track for Largest Percent Increase Since March 2020 — Data Talk
Emerson Electric Co. (EMR) is currently at $104.25, up $9.99 or 10.6%
--Would be highest close since Sept. 3, 2021, when it closed at $105.38
--On pace for largest percent increase since March 24, 2020, when it rose 16.33%
--Currently up four of the past five days
--Currently up two consecutive days; up 11.62% over this period
--Best two day stretch since the two days ending March 25, 2020, when it rose 25.03%
--Up 13.65% month-to-date
--Up 7.11% year-to-date
--Down 1.37% from its all-time closing high of $105.70 on Sept. 2, 2021
--Up 21.24% from 52 weeks ago (Feb. 8, 2023), when it closed at $85.99
--Would be a new 52-week closing high
--Up 34.2% from its 52-week closing low of $77.68 on May 31, 2023
--Traded as high as $104.40; highest intraday level since Sept. 7, 2021, when it hit $105.09
--Up 10.76% at today's intraday high; largest intraday percent increase since March 25, 2020, when it rose as much as 12.73%
--Second best performer in the S&P 500 today
All data as of 10:06:12 AM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
February 07, 2024 10:23 ET (15:23 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track